Neurotrope Falls 55% After Alzheimer's Drug Results Come Under Scrutiny

Neurotrope Inc NTRP shares are trading lower by $10.50 (55 percent) or 55 percent at $8.31 in Monday's session after Phase 2 results came out less than positive.

The issue is in a freefall after Adam Feuerstein spoke on Benzinga's PreMarket Prep and exposed the actual results of what the company deemed as a positive for Bryostatin for the treatment for Alzheimer's disease.

See Also: Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance

Adding to the selling pressure is Friday's who anticipated good results and purchased shares  during its rally from Thursday's close of $15.13 to $18.81.

After being pounded in the pre-market session, Neurotrope's stock could only manage a nickel bounce of its nearly $9.00 lower opening print to $10.05 before continuing its move lower.

So far, the ensuing decline has taken the stock to $8.16 and it's attempting to mount a rebound. Despite the rout in today's session, the issue is still in the green for 2017, as it ended 2016 at $7.52.